HiberCell
  • About
    • Mission
    • Team
  • Our Science
    • Overview
    • Odetiglucan
    • HC-5404
    • HC-7366
  • Pipeline
  • Patients & Caregivers
  • News & Publications
  • Contact
  • Careers
  • About
    • Mission
    • Team
  • Our Science
    • Overview
    • Odetiglucan
    • HC-5404
    • HC-7366
  • Pipeline
  • Patients & Caregivers
  • News & Publications
  • Contact
  • Careers

Publication Topic: Odetiglucan (dectin-1)

A Phase 1b, Open-Label, 2-part, Safety, Tolerability, and Efficacy Study of a Soluble Beta-Glucan (Odetiglucan) in Combination with a CD40 Agonistic Monoclonal Antibody (CDX-1140) in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Did Not Progress During First-Line (1L) Chemotherapy

Cancer immunotherapy via myeloid signaling pathway co-activation (Wattenberg et al. AACR Pancreatic Cancer 2022)

Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies

A novel, phase 2 study in second line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG

Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan

Response and clinical benefit assessment of the combination of the dectin-1 agonist Imprime PGG and anti-PD-1 pembrolizumab in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)

Association of immunopharmacodynamic responses of Imprime PGG plus pembrolizumab with clinical benefit in metastatic triple negative breast cancer (TNBC) subjects failing front-line chemotherapy

Clinical benefit evident with early immunopharmacodynamic responses in prior checkpoint failed metastatic melanoma patients treated with Imprime PGG and pembrolizumab

Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers

Imprime (β-1,3/1,6 glucan) synergizes with a CD40 agonist to stimulate T cell-dependent antitumor activity in a poorly immunogenic model of pancreatic carcinoma

Posts navigation

Older posts
HiberCell
  • About
    • Mission
    • Team
  • Our Science
    • Our Science
    • Odetiglucan
    • HC-5404
    • HC-7366
  • Pipeline
  • News & Publications
  • Contact
  • Careers
Linked In

© 2023 Hibercell Inc |
Privacy Policy |
Terms & Conditions |
Expanded Access